Etoetonitazene
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C24H32N4O4 |
| Molar mass | 440.544 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Etoetonitazene is a benzimidazole derivative with opioid effects, first developed in the 1950s as part of the research that led to better-known compounds such as etonitazene. It is an analogue of etonitazene where the ethoxy sidechain has been extended to ethoxyethoxy. It is less potent than other benzimidazole class opioids, but is still a potent mu opioid receptor agonist with around 50x the potency of morphine, and has been sold as a designer drug since around 2022.[1][2]
See also
References
- ^ "A review of the evidence on the use and harms of 2-benzyl benzimidazole ('nitazene') and piperidine benzimidazolone ('brorphine-like') opioids" (PDF). UK: Advisory Council on the Misuse of Drugs. July 2022.
- ^ Hasegawa K, Minakata K, Suzuki M, Suzuki O (July 2022). "Non-fentanyl-derived synthetic opioids emerging during recent years". Forensic Toxicology. 40 (2): 234–243. doi:10.1007/s11419-022-00624-y. PMC 9052731. PMID 36454418.